Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.43 +0.55 (+1.06%)

Delayed Quote Updated: 11:47 AM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Volume	611,656
Open	52.49
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	51.88
Today's Range	52.05 - 52.52
52wk Range	40.05 - 60.85
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends

Today 7:00 EDT

From Genentech

Via Business Wire

Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions

Today 2:00 EDT

From Genentech

Via Business Wire

Performance

YTD	+1.9%	+1.9%
1 Month	-2.4%	-2.4%
3 Month	+4.2%	+4.2%
6 Month	+4.0%	+4.0%
1 Year	+25.4%	+25.4%

More News

Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine

Today 1:00 EDT

From Genentech

Via Business Wire

Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market? ↗

September 30, 2026

Via The Motley Fool

Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis

September 30, 2026

From Genentech

Via Business Wire

Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon

September 28, 2026

From Genentech

Via Business Wire

Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)

September 23, 2026

From Genentech

Via Business Wire

Is Regeneron Stock a Bargain Below $800? ↗

September 22, 2026

Via The Motley Fool

Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity

September 22, 2026

From Genentech

Via Business Wire

BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗

September 18, 2026

Via The Motley Fool

Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center

September 17, 2026

From Genentech

Via Business Wire

Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study

September 17, 2026

From Genentech

Via Business Wire

U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments

September 10, 2026

From Genentech

Via Business Wire

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

Via Investor Brand Network

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Via Investor Brand Network

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Via Investor Brand Network

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Via Investor Brand Network

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

From BioMedWire

Via GlobeNewswire

Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗

September 04, 2026

Via MarketBeat

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗

September 03, 2026

Via The Motley Fool

2 Stocks That Could Capitalize on the GLP-1 Boom ↗

August 25, 2026

Via The Motley Fool

Genentech Announces Manufacturing Expansion in Hillsboro, Oregon

August 20, 2026

From Genentech

Via Business Wire

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

August 18, 2026

From Genentech

Via Business Wire

2 GLP-1 Stocks That Could Double Your Money by 2031 ↗

August 16, 2026

Via The Motley Fool

Vanguard Is Bullish on Developed Markets Outside the U.S. -- But How Can You Buy Them? These 2 ETFs Can Help. ↗

August 14, 2026

Via The Motley Fool

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?

Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.

What exchange does Roche Holding AG Basel American Depositary Shares trade on?

Roche Holding AG Basel American Depositary Shares trades on the OTC Traded

What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?

The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded

What is the current price of Roche Holding AG Basel American Depositary Shares?

The current price of Roche Holding AG Basel American Depositary Shares is 52.43

When was Roche Holding AG Basel American Depositary Shares last traded?

The last trade of Roche Holding AG Basel American Depositary Shares was at 10/01/26 11:47 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.